- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07815574
iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma (SCOPE Plus)
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive Study of iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma
This Phase 3 clinical trial is evaluating whether adding iSCIB1+, an investigational DNA-based cancer vaccine, to standard immunotherapy with nivolumab and ipilimumab can improve outcomes for people with advanced unresectable melanoma.
Participants will be randomly assigned to receive either iSCIB1+ or a placebo, in addition to standard treatment with nivolumab and ipilimumab. Neither participants nor study doctors will know which treatment has been assigned. The study will compare how long participants live without their cancer worsening, overall survival, tumor response, safety, and quality of life.
iSCIB1+ is designed to stimulate the immune system to recognize and attack melanoma cells by targeting proteins commonly found on melanoma tumors. Earlier studies have shown encouraging signs of immune activation and anti-tumor activity when iSCIB1+ was combined with checkpoint inhibitor immunotherapy. This study aims to determine whether adding iSCIB1+ to standard immunotherapy provides additional benefit compared with standard immunotherapy alone
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of iSCIB1+ in combination with nivolumab and ipilimumab as first-line treatment for adults with advanced unresectable Stage III or Stage IV melanoma who express specific human leukocyte antigen (HLA) types.
Checkpoint inhibitor therapy has significantly improved outcomes for patients with advanced melanoma; however, many patients still experience disease progression. iSCIB1+ is a DNA-based therapeutic cancer vaccine designed to enhance immune recognition of melanoma-associated antigens and may improve the depth and durability of anti-tumor responses when used alongside checkpoint inhibition.
Approximately 550 participants will be randomized in a 1:1 ratio to receive either:
iSCIB1+ plus nivolumab and ipilimumab, or Placebo plus nivolumab and ipilimumab.
The primary objective is to determine whether the addition of iSCIB1+ improves progression-free survival (PFS) compared with placebo when both are administered in combination with nivolumab and ipilimumab.
Secondary objectives include evaluation of:
Overall survival (OS) Objective response rate (ORR) Duration of response (DoR) Disease control rate (DCR) Safety and tolerability Patient-reported quality of life outcomes
The study will also explore immune and biomarker responses in selected participants to better understand the relationship between vaccine-induced immune responses and clinical outcomes.
Participants will continue to be followed for disease progression, survival, safety, and other outcomes for up to four years after randomization.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Joe Thornton
- Phone Number: 44 (0) 1865 582 066
- Email: joethornton@scancell.co.uk
Study Contact Backup
- Name: Olivia Howard
- Phone Number: 44 (0) 1865 582 066
- Email: oliviahoward@scancell.co.uk
Study Locations
-
-
-
London, United Kingdom
- Mount Vernon Cancer Centre
-
Principal Investigator:
- Heather Shaw
-
-
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Cancer Center
-
Principal Investigator:
- Sapna Patel
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
5.1.Inclusion Criteria
- Participant has histologically confirmed, unresectable Stage III or Stage IV melanoma as defined by the AJCC (Gershenwald et al., 2017). Participants with a diagnosis of melanoma of unknown primary are eligible.
- Participant is positive for at least one of the following HLA alleles: HLA- with an HLA type of any one of HLA MHC class I: A2, A3, A31, Bw4, B44 and B35.
- Participant has been clinically evaluated, and checkpoint inhibition has been determined to be an appropriate treatment for their advanced disease.
- Participant's BRAF status must be known; participants with BRAF mutation positive disease may be enrolled without BRAF-inhibitor treatment at the discretion of the Study Investigator.
- Participant has at least one measurable lesion per RECIST 1.1 criteria by computed tomography CT scan or MRI.
- Participant is at least 18 years of age.
- Participant has a life expectancy of more than 6 months.
- Participant has an ECOG performance status of 0 or 1.
Participant has adequate organ function as determined by the following laboratory values:
Absolute neutrophil count ≥ 1.5 x 109/L Lymphocyte count ≥0.5 x 109/L Platelet count ≥100 x 109/L Hemoglobin >9 g/dL (> 5.6 mmol/L) Serum creatinine or creatinine clearance ≤1.5x ULN >50 mL/min Serum total bilirubin ≤1.5 x ULN or <3.0 mg/dL if participant has Gilbert's syndrome Serum transaminases, AST and ALT ≤2.5 x ULN or ≤5.0 x ULN if liver metastases present
- Participant must be able and willing to provide written IRB/REC-approved informed consent prior to any study-related procedure.
Women of childbearing potential must agree to use highly effective contraceptive methods prior to study entry, for the whole duration of study treatment, and for at least 5 months following the last dose or in accordance with the SmPC of the IC SOC CPI (whichever is most conservative).
See Appendix D: Guidance on Acceptable Contraceptive Methods for full guidance..
- Women of childbearing potential must have a negative serum pregnancy test at screening and within two days before IMP (or placebo) administration.
- Participant must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.
5.2.Exclusion Criteria
- Participant has a diagnosis of mucosal, ocular or acral melanoma.
- Participant has received prior systemic anti-PD1 treatment for advanced disease.
- Participant has received prior adjuvant treatment, defined as treatment following resection of all detectable disease, within 6 weeks of Day 1 (first dose of IMP).
- Participant has BRAF mutation positive disease with evidence of rapid PD.
- Participant has symptomatic brain metastases or carcinomatous meningitis. Symptomatic brain metastases are defined as brain metastases causing neurological signs or symptoms attributable to intracranial disease and/or requiring corticosteroid therapy for the management of brain metastasis-related symptoms. Participant is expected to require and elect any other form of systemic or localized anticancer therapy while receiving study treatment.
- Participants receive treatment with any investigational product within 28 days (or five half-lives of the treatment concerned if longer than 28 days) prior to Day 1.
- Participant has had a previous or current malignancy within 5 years, with the exception of melanoma and curatively treated local tumors.
- Participant has a concurrent illness/diagnosis which are uncontrolled and/or would preclude study conduct and assessment.
- Participant has NYHA class III or IV heart disease.
- Participant has a history of severe hypersensitivity reaction to treatment with a mAb.
- Participant has an active autoimmune disease or a documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents above physiological dosing.
- Received a live vaccine or non-live vaccine (including COVID-19 vaccines) within 7 days prior to first dose of study treatment.
- Participant has received systemic steroids or is receiving any other form of immune suppressant medication above physiological dosing within 7 days of Day 1.
- Participant is positive for HIV-1/2 infection or is positive for HBsAg or HCV antigen consistent with active infection.
- Participant has a known current or recent history (within the last year) of substance abuse including illicit drugs or alcohol to the extent where it would negatively affect compliance with the trial protocol based on Study Investigator's decision.
- Participant has received a solid organ transplant.
- Participant is breastfeeding during the study treatment phase, and for at least five months following the last dose or in accordance with the SmPC of I/N (whichever is most conservative).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: iSCIB1+ in combination with Ipilimumab and Nivolumab
Participants will receive iSCIB1+ in combination with standard immunotherapy consisting of nivolumab and ipilimumab.
Treatment will be administered according to the protocol-defined dosing schedule.
Following induction treatment with nivolumab and ipilimumab, participants will continue nivolumab maintenance therapy.
This arm is designed to evaluate whether the addition of iSCIB1+ improves clinical outcomes compared with placebo when administered in combination with nivolumab and ipilimumab in participants with advanced unresectable melanoma.
|
iSCIB1+ is a DNA-based therapeutic cancer vaccine designed to enhance T-cell immune responses against melanoma-associated antigens.
The vaccine encodes epitopes derived from glycoprotein 100 (gp100) and tyrosinase-related protein 2 (TRP-2) that are delivered using Scancell's ImmunoBody® platform.
In this study, iSCIB1+ is administered by intramuscular injection with electroporation in combination with nivolumab and ipilimumab for the treatment of advanced unresectable melanoma.
The intervention is intended to augment anti-tumor immune responses and improve clinical outcomes when added to standard checkpoint inhibitor therapy.
Other Names:
Nivolumab is a programmed death-1 (PD-1) immune checkpoint inhibitor monoclonal antibody administered according to the protocol-defined treatment regimen.
Ipilimumab is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) immune checkpoint inhibitor monoclonal antibody administered according to the protocol-defined treatment regimen.
Other Names:
|
|
Placebo Comparator: Placebo + Nivolumab and Ipilimumab
Participants will receive placebo in combination with standard immunotherapy consisting of nivolumab and ipilimumab.
Treatment will be administered according to the protocol-defined dosing schedule.
Following induction treatment with nivolumab and ipilimumab, participants will continue nivolumab maintenance therapy.
This arm serves as the comparator for evaluating the efficacy and safety of iSCIB1+ when added to standard first-line immunotherapy in participants with advanced unresectable melanoma.
|
Nivolumab is a programmed death-1 (PD-1) immune checkpoint inhibitor monoclonal antibody administered according to the protocol-defined treatment regimen.
Ipilimumab is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) immune checkpoint inhibitor monoclonal antibody administered according to the protocol-defined treatment regimen.
Other Names:
The placebo is a Dulbecco's Phosphate-Buffered Saline (D-PBS) solution for intramuscular injection that contains no iSCIB1+ plasmid DNA.
It is formulated to be visually and physically indistinguishable from iSCIB1+ and is administered using the same procedures to maintain study blinding.
The placebo serves as the comparator in this trial when administered in combination with nivolumab and ipilimumab.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Progression-Free Survival (PFS)
Time Frame: Up to 4 years after randomization.
|
Progression-free survival (PFS), defined as the time from randomization to the earliest occurrence of disease progression per RECIST v1.1 as assessed by Blinded Independent Central Review (BICR) or death from any cause.
|
Up to 4 years after randomization.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall Survival (OS)
Time Frame: Up to approximately 4 years months after randomization.
|
Overall survival, defined as the time from randomization to death from any cause.
|
Up to approximately 4 years months after randomization.
|
|
Objective Response Rate (ORR)
Time Frame: Up to 4 years after randomization.
|
Objective response rate, defined as the proportion of participants achieving a confirmed complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by BICR.
|
Up to 4 years after randomization.
|
|
Duration of Response (DoR)
Time Frame: Up to 4 years after randomization.
|
Duration of response, defined as the time from first documented objective response (CR or PR) until disease progression per RECIST v1.1 or death from any cause.
|
Up to 4 years after randomization.
|
|
Disease Control Rate (DCR)
Time Frame: Up to 4 years after randomization.
|
Disease control rate, defined as the proportion of participants achieving complete response, partial response, or stable disease according to RECIST v1.1 as assessed by BICR.
|
Up to 4 years after randomization.
|
|
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Time Frame: From informed consent and up to 4 years from randomization
|
Incidence, nature, severity, and relationship of treatment-emergent adverse events, graded according to NCI CTCAE.
|
From informed consent and up to 4 years from randomization
|
|
Incidence of Serious Adverse Events (SAEs)
Time Frame: From informed consent and up to 4 years from randomization
|
Incidence of serious adverse events.
|
From informed consent and up to 4 years from randomization
|
|
Change from baseline in EORTC QLQ-C30 Global Health Status/Quality of Life score
Time Frame: From informed consent and up to 4 years from randomization
|
The EORTC QLQ-C30 Global Health Status/Quality of Life scale ranges from 0 to 100, with higher scores indicating better quality of life.
|
From informed consent and up to 4 years from randomization
|
|
Change from baseline in EQ-5D-5L Health Utility Index Score
Time Frame: From informed consent and up to 4 years from randomization
|
EQ-5D-5L index values are derived from participant responses across five health dimensions.
|
From informed consent and up to 4 years from randomization
|
|
Number of participants reporting symptomatic adverse events according to PRO-CTCAE items
Time Frame: From informed consent and up to 4 years from randomization
|
Participant-reported symptom burden will be assessed using selected PRO-CTCAE symptom items.
Individual responses are scored according to the PRO-CTCAE scoring manual.
|
From informed consent and up to 4 years from randomization
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Immune Response to iSCIB1+: Change from baseline in antigen-specific T-cell response measured by IFN-γ ELISpot assay
Time Frame: From informed consent and up to 4 years from randomization
|
Antigen-specific cellular immune responses to TRP-2 and gp100 melanoma antigens will be evaluated using IFN-γ ELISpot assays on peripheral blood samples collected from a subset of participants.
|
From informed consent and up to 4 years from randomization
|
|
Change from baseline in exploratory tumor, blood, and immune biomarker levels
Time Frame: From informed consent until completion of study participation (i.e. up to 4 years)
|
Analysis of changes in exploratory tumor, blood, and immune biomarkers measured in tissue and blood samples collected during the study.
Biomarker measurements may include gene expression, circulating tumor DNA, immune cell populations, cytokines, and other exploratory markers.
|
From informed consent until completion of study participation (i.e. up to 4 years)
|
|
Change from baseline in exploratory immune-related biomarker measurements
Time Frame: From baseline and up to 4 years from day 1.
|
Exploratory assessment of changes in immune-related biomarkers, including PD-1, PD-L1, CTLA-4, CD3+, CD4+, CD8+ cell markers, cytokines, T-cell receptor repertoire, tumor infiltrating lymphocytes, and circulating tumor DNA measured in tumor tissue and blood samples.
|
From baseline and up to 4 years from day 1.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Neoplasms by Histologic Type
- Skin Diseases
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Skin and Connective Tissue Diseases
- Melanoma
- Skin Neoplasms
- Amino Acids, Peptides, and Proteins
- Proteins
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal
- Antibodies
- Immunoglobulins
- Immunoproteins
- Blood Proteins
- Serum Globulins
- Globulins
- Nivolumab
- Ipilimumab
Other Study ID Numbers
- SCIB1-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.